Medical Letter on the CDC and FDA

Cardiology - DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA

Clinical Trial Research - Oculus Innovative Sciences Announces Completion of Two Randomized Controlled Clinical Trials of Microcyn(R) Technology in China

Cloning - Top U.S. Cloning Companies Announce New System to Track Cloned Livestock

Cystinosis - Raptor Pharmaceuticals Acquires Orphan Clinical Program

Diagnostic Imaging - GE Healthcare Announces Expansion of Nuclear Cardiology Portfolio for Medical Diagnostics Business

Drug Development - ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)

Drug Development - Ligand Earns $1 Million Milestone Payment as GlaxoSmithKline Submits New Drug Application for PROMACTA(R) (eltrombopag)

Drugs - Nanotechnology Regulators Make News

Food and Drug Law Institute - Food and Drug Law Institute Sponsors Major Enforcement Conference

GlaxoSmithKline - GlaxoSmithKline Completes Acquisition of Reliant Pharmaceuticals

Hanley Center - Baseball Bombshell Lesson: Illegal Steroid Use Dangerous to Young Athletes

Head and Neck Cancer - Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008

Heart Attack - Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction

Heart Failure - New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration

Heart Failure - Vasogen Provides an Update on ACCLAIM-II Preparations

Hematology - Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System

HIV/AIDS - European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virolo

HIV/AIDS - Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration

Hospira, Inc. - Hospira's Retacrit(TM) Receives Marketing Authorization in the EU

Hypertension - Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension

ImaRx Therapeutics, Inc. - ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating

Immunization - DHL, UNICEF, Sanofi and HPIC Team up to Deliver Life-Saving Vaccines to Children of Uzbekistan

Indevus Pharmaceuticals, Inc. - Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)

IRIS International, Inc. - IRIS Submits 510(k) Application to FDA for Its iChem(R)VELOCITY(TM) Automated Urine Chemistry Analyzer

Marketing and Licensing Agreements - BioSante Pharmaceuticals Receives Milestone Payment from Bradley Pharmaceuticals

Mesothelioma - Weitz & Luxenberg Recognizes New Advance in Mesothelioma Treatment

Monogram Biosciences, Inc. - Study Reaffirms Superiority of Trofile(TM) Assay

Myeloma - Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

Non-Small Cell Lung Cancer - Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule

Outside Labs, Inc. - K2 Sports Announces New Endurance Suncare Product Rollout for 2008

PARI Innovative Manufacturers - PARI Hydrate Receives FDA Clearance

Pediatrics - JSI Receives Grant From the Bill & Melinda Gates Foundation to Improve Health in Ethiopia

Peregrine Pharmaceuticals, Inc. - Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program

Psoriasis - Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis

Public Health - UPDATE: Significant Progress Made in Nation's Preparedness to Respond to Public Health Emergencies; but Gaps in Critical Areas Threaten Overall Readiness

Regulatory Actions - Advertisements for Medical Devices, Implants Should Carry Warnings of Dangerous Side Effects, Infections

Regulatory Actions - Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit

Regulatory Actions - GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

Regulatory Actions - IMPAX Announces FDA Acceptance of ANDA for Generic Version of Opana(R) ER

Regulatory Actions - Ontario Ministry of Health Implements Tumbleweed to Secure Transfer of Patient Data

Regulatory Actions - Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)

Schering-Plough Corporation - MiraLAX(R) #1 in Non-Fiber OTC Laxative Category

Sickle Cell Anemia - Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

Starpharma - FDA Warning for N-9 - an Opportunity for VivaGel(R)

Thyroid Cancer - Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation

Transdermal Delivery - Antares Pharma Receives Milestone Payment

Von Willebrand Disease - CSL Behring Expands Into Middle East Market with Haemate(R) P